Ceragenix PharmaceuticalsPharmaceuticals Ceragenix
ssung class="mw-headline" id="Produkte">Produkte
Keragenix Pharmaceuticals, Inc. is a Denver, Colorado-based bio-pharmaceutical corporation developing ethical drug candidates using a combination of patented surfactant technology platforms - skin barrier repair technology (BRT) and Cerageninis, a new generation of broad-spectrum anti-infectives. Biotech Discovery discovered, developed and marketed anti-infectives on the basis of its own drug category Ceragenine.
Effective against a variety of Gram-positive and Gram-negative bacterial pathogens, these compounds are being formulated as anti-infective drug delivery systems and as therapeutic products for antibiotic-resistant pathogens. EpiCeram was invented by Ceragenix. This is a non-autroid topical dermatological creme derived from Peter Elias' research on the therapy of neurodermatitis.
Ceragenix's second multi-drug platforms address multi-drug resistance of bacteria and virals. Antiinfectives vaccine research is predicated on the research of Dr. Paul B. Savage, Professor and Associate Chair of Departments of Chemistry and Biochemistry at Brigham Young University (BYU, Provo, Utah). This compound is an aminosterol that mimics the activities of natural antibiotic agents that are part of the body's immunity system and early line of defence against bacteria, virus, fungus and certain cancer.
Ceragenins have been analysed in vitro and have shown a number of measures against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), tobramycin-resistant Pseudomonas aeruginosa aureus ( PATR), Escherichia coli, Vakinia viral, HIV and Baccillus antracis (Anthrax), among others. Connections work by breaking through the external membrane of their target.
Connections are positive charge and are drawn electrically by negative charge phosphospholipids, which have a tendency to differentiate precaryotic from eucaryotic ions.
OTCBB:CGXP OnSource Corporation changes name to Ceragenix Pharmaceuticals
DENVER, June 27, 2005 (PRIMEZONE) -- OnSource Corporation ("OnSource") has renamed itself Ceragenix Pharmaceuticals, Inc. Following OnSource's May 11, 2005 amalgamation with Osmotics Pharma, Inc., the name changes reflect the company's renewed focus and dedication to providing leading-edge solutions for skin and communicable diseases.
"cThis important move confirms our strategy to establish a new bio-pharmaceutical business around our two platforms technologies,â said Steven Porter, Chairman and CEO of Ceragenix. "It is a very exhilarating period for our business as we enter into the first commercialisation of our medicinal products, which includes the forthcoming expected 510k submission of EpiCeram(tm), the first topically formulated of our barriere reparation technique, and the further advancement of our proprietary cationic steroid antibiotic technique for potentially long-lived anti-microbial coating for medicinal products.
It is a great pleasure for us to move forward under the name Ceragenix Pharmaceuticals. "In connection with this name shift, Ceragenix Pharmaceuticals is now listed on the OTC Bulletin Board under the CGXP icon with effect from the opening of the store on Monday, June 27, 2005. Seragenix is a privately held biotechnology and life science drug discovery and production group focusing on skin and skin diseases.
Ceragenix's proprietary barrier repair technique, developed by Dr. Peter Elias and licenced by the University of California, is the foundation for the discovery of two ethical topically prescribed cream products - EpiCeram(tm) and NeoCeram(tm) - that create identically shaped barrier layers. CSA' proprietary Cationic Steroid Antibiotic (CSA) antibiotic formulation forms the foundation for its novel anti-microbial coatings on various types of healthcare products that can be applied to ensure potentially long-lasting anti-microbial activities.
Some of Ceragenix's products are also planned to be developed as topically and systemically active antibiotics for the management of cutaneous respiratory distress (MRSA), burns, ocular respiratory and other conditions. There may be forward-looking information in this news release. Under the Private Securities Litigation Reform Act of 1995, forward-looking information is provided in a secure haven.
Such forward-looking information is inherently risky and uncertain and could cause results to differ materially from those projected or indicated in such forward-looking information, which includes, but is not limited to, the Company's ability to fund its proposed operations, to obtain the necessary regulatory approval from the FDA, to conduct prospective studies with the Company's proposed technologies, to promote the Company's proposed technologies, to gain commercial acceptance for its proposed technologies, to successfully penetrate the markets for the Company's proposed technologies and to successfully penetrate the markets for its proposed technologies.
Whilst corporate governance considers that the forward-looking statement is based on an appropriate set of beliefs, any of the beliefs could be incorrect and there can be no guarantee that the forward-looking statement will be correct. Given the material uncertainty surrounding the forward-looking statement, the incorporation of such information should not be taken as an undertaking by the entity or any other individual that the entity's goals and intentions will be attained.
More information can be found in the Company's records with the SEC, which include SB-2, 10-KSB, 10-QSB, and 8-K forms. There is no undertaking by the Corporation to revise any forward-looking statement to conform with future events or changes in circumstances that affect such forward-looking statement.